Antiplatelet resistance among a cohort of patients at risk of atherosclerotic cardiovascular diseases in Jos, Nigeria

Author:

Okeahialam Basil Nwaneri1,Akor Emmanuel2,Shut Gabriel1,Ifeacho Ogo1,Dauda Bangalu2,Sirisena Anil3,Amusa Ganiyu Adeniyi1

Affiliation:

1. Department of Medicine, Jos University Teaching Hospital, Jos, Plateau, Nigeria,

2. Department of Haematology, Jos University Teaching Hospital, Jos, Plateau, Nigeria,

3. Department of Radiology, Jos University Teaching Hospital, Jos, Plateau, Nigeria,

Abstract

Objectives: Patients with atherosclerotic cardiovascular diseases (ASCVDs) are predisposed to atherothrombosis and ischemic phenomena. Antiplatelets mitigate this but not consistently, as these ischemic events still occur despite their administration. This is called antiplatelet resistance. We sought to see how much of this occurs in our patients since its rate is bound to differ from place to place. The burden of antiplatelet resistance has not been determined in our environment. Material and Methods: Patients at risk of ASCVD who were receiving antiplatelet treatments were invited to participate in this study. They were enrolled first into a two week wash out phase, after which baseline aggregometry and full blood count were done. They were then given either Aspirin or Clopidogrel for four weeks and had the same blood work-up repeated. The Aggregometer was used to determine the platelet aggregability at these different times. If the second set showed >10% reduction from baseline, such patients were adjudged sensitive. A reduction <10% of the first value defined resistance. Results: Twenty patients (15 F/5 M) were in Group 1 and received a low dose of Aspirin (75 mg), the age range of 42–76 years, with a mean (standard deviation [SD]) of 60.75 (10.45). Twenty-six were in Group 2 (18 F/8 M) and received low dose clopidogrel (75 mg), with an age range of 23–87 years and a mean (SD) of 58.08 (14.18). Fifteen (75%) were sensitive in Group 1 (Aspirin) with 25% resistant. For Clopidogrel, 14 (53.85%) were sensitive and 12 (46.15%) resistant. In a few cases, the aggregability actually increased paradoxically on treatment. Conclusion: Antiplatelet resistance also occurs in our environment; it is worse for Clopidogrel than for Aspirin. These are people who, despite being on antiplatelets, would go on to develop these atherothrombotic ischemic phenomena. Efforts to identify the predictors of this phenomenon of resistance and work out effective counteractions should be encouraged.

Publisher

Scientific Scholar

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3